JPH0595767A - Health food with gamma-polyglutamic acid as the chief ingredient - Google Patents
Health food with gamma-polyglutamic acid as the chief ingredientInfo
- Publication number
- JPH0595767A JPH0595767A JP3260630A JP26063091A JPH0595767A JP H0595767 A JPH0595767 A JP H0595767A JP 3260630 A JP3260630 A JP 3260630A JP 26063091 A JP26063091 A JP 26063091A JP H0595767 A JPH0595767 A JP H0595767A
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- μmol
- polyglutamic acid
- amount
- pga
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Non-Alcoholic Beverages (AREA)
- Confectionery (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は健康飲食品に関する。FIELD OF THE INVENTION The present invention relates to health foods and drinks.
【0002】[0002]
【従来の技術及び発明が解決しようとする課題】γ−ポ
リグルタミン酸は納豆菌の生産するポリアミノ酸の代表
例として知られている。その優れた粘性と水溶性食物繊
維の性質を利用する飲料素材としての可能性について
は、既に知られている。特開平2−249474。一
方、カルシウム吸収効果を有する食品素材として、カゼ
インホスホペプチドが知られている。特公平2−761
6。本発明者らは新しい、カルシウム吸収促進効果を有
する食品素材として、γ−ポリグルタミン酸を検討し
た。2. Description of the Related Art γ-Polyglutamic acid is known as a representative example of polyamino acid produced by Bacillus natto. The possibility as a beverage material utilizing the excellent viscosity and the property of water-soluble dietary fiber is already known. JP-A-2-249474. On the other hand, casein phosphopeptide is known as a food material having a calcium absorbing effect. Japanese Patent Publication No. 2-761
6. The present inventors examined γ-polyglutamic acid as a new food material having a calcium absorption promoting effect.
【0003】[0003]
【課題を解決するための手段】本発明者らは、γ−ポリ
グルタミン酸又はその塩が優れたカルシウム促進効果を
有することをみつけた。これを食品に添加し、これを食
することにより可溶性カルシウムとして生体内に吸収で
きるようにしたカルシウム吸収促進効果の優れた健康飲
食品を発明した。The inventors of the present invention have found that γ-polyglutamic acid or a salt thereof has an excellent calcium promoting effect. The present invention has invented a healthy food or drink product which is added to food and can be absorbed in the body as soluble calcium by eating it, which has an excellent effect of promoting calcium absorption.
【0004】本発明に使用するγ−ポリグルタミン酸
は、食品に含有せしめるものであるから、十分精製した
ものを使用することが必要である。納豆菌由来、その他
の微生物由来のもので分子量1000〜200万のもの
であれば使用可能である。その塩はNa塩、又は食品素
材として好ましく、カルシウム吸収促進効果を減弱しな
いものであれば特に限定されない。共存するカルシウム
イオンの量は、γ−ポリグルタミン酸又はその塩1mg
に対し、5μモル〜50μモルの範囲が好ましい。Since the γ-polyglutamic acid used in the present invention is contained in foods, it is necessary to use a sufficiently purified product. It can be used as long as it is derived from Bacillus natto and other microorganisms and has a molecular weight of 1,000 to 2,000,000. The salt is preferable as a Na salt or food material, and is not particularly limited as long as it does not reduce the calcium absorption promoting effect. The amount of coexisting calcium ions is 1 mg of γ-polyglutamic acid or its salt.
On the other hand, the range of 5 μmol to 50 μmol is preferable.
【0005】本発明に適合するγ−ポリグルタミン酸ナ
トリウム(分子量約125万)(明治製菓社製)を以下
PGAと略記する。PGAがカルシウムの吸収に効果的
に作用するためには、小腸管腔内で可溶化カルシウムを
増加させ、リン酸カルシウムの生成を抑制することが必
要である。PGAは市販のカゼインホスホペプチド(C
PP−III ,明治製菓社製)に比べ、リン酸量の増加に
よる影響が少なく、優れたカルシウム吸収促進効果が認
められた。Sodium γ-polyglutamate (molecular weight about 1.25 million) (manufactured by Meiji Seika Co., Ltd.) which is suitable for the present invention is hereinafter abbreviated as PGA. In order for PGA to effectively act on calcium absorption, it is necessary to increase solubilized calcium in the lumen of the small intestine and suppress calcium phosphate production. PGA is a commercially available casein phosphopeptide (C
PP-III, manufactured by Meiji Seika Co., Ltd.), the effect of increasing the amount of phosphoric acid was less, and an excellent calcium absorption promoting effect was observed.
【0006】本発明の飲食品としては菓子類例えば錠
菓、ビスケット等、飲料例えば炭酸飲料、乳酸飲料等が
ある。食品に添加する場合、その添加割合には特に制限
はない。しかし経済性を考慮して一般に菓子類の場合は
1〜30%それらの原料に加えればよい。飲料の場合は
0.5〜10%程度製品に添加すればよい。The food and drink of the present invention include confectionery such as tablet confectionery and biscuits, and beverages such as carbonated beverages and lactic acid beverages. When it is added to food, there is no particular limitation on the addition ratio. However, in consideration of economy, in the case of confectionery, in general, 1 to 30% may be added to the raw materials thereof. In the case of a beverage, about 0.5 to 10% may be added to the product.
【0007】[0007]
実施例1Ca(カルシウム量)−P(リン酸量)当量におけるP
GAとCPP−III のカルシウム可溶化能 PGA(明治製菓社製、分子量約125万)又はCPP
−III (明治製菓社製)溶液0〜 0.35ml(PG
Aは0〜4.9mg,CPP−IIIは0〜0.7mg)
にカルシウム溶液(CaCl2 ・2H2 Oの40mM溶
液)0.4ml(16μモル)を加え、蒸留水で2.8
75mlとし一定量とした後、リン酸溶液(0.5M
NaH2 PO3 と0.5N NaOH溶液から40mM
リン酸ナトリウム緩衝液(pH7.4)を調製して用い
た。)0.625ml(25μモル)を加え、上清のカ
ルシウム濃度を測定した。測定は全量を3.8mlとし
た後、37℃で2.5時間放置したあと、3000rp
m、5分間遠心し、上清の可溶体カルシウムを酵素法
(OCPC法、カルシウムCテスト・ワコー)で測定し
た。Example 1 P in Ca (calcium amount) -P (phosphoric acid amount) equivalent
GA and CPP-III calcium solubilizing ability PGA (Meiji Seika Co., Ltd., molecular weight about 1.25 million) or CPP
-III (Meiji Seika Co., Ltd.) solution 0 to 0.35 ml (PG
(A is 0 to 4.9 mg, CPP-III is 0 to 0.7 mg)
To the solution, 0.4 ml (16 μmol) of a calcium solution (40 mM solution of CaCl 2 .2H 2 O) was added, and distilled water was added to 2.8.
After adjusting the volume to 75 ml and adjusting to a fixed volume, phosphoric acid solution (0.5M
40 mM from NaH 2 PO 3 and 0.5N NaOH solution
A sodium phosphate buffer (pH 7.4) was prepared and used. ) 0.625 ml (25 μmol) was added and the calcium concentration in the supernatant was measured. After measuring the total volume to 3.8 ml, leave it at 37 ° C for 2.5 hours and then 3000 rp.
After centrifugation for 5 minutes, the soluble calcium in the supernatant was measured by an enzymatic method (OCPC method, calcium C test Wako).
【0008】その結果、加えたカルシウム量の50%
(8μモル)を可溶化させるのにPGAは1mg、CP
P−III は0.36mgを必要とし、80%以上を可溶
化させるのにPGAは1.4mg、CPP−III は0.
56mgを必要とした。尚、全量可溶化させるのにPG
Aは4.9mg、CPP−III は0.7mgを必要とし
た。As a result, 50% of the added calcium amount
1 mg of PGA and CP to solubilize (8 μmol)
P-III requires 0.36 mg, PGA is 1.4 mg and CPP-III is 0.1 mg to solubilize 80% or more.
56 mg was needed. In addition, to solubilize the whole amount, PG
A required 4.9 mg and CPP-III required 0.7 mg.
【0009】実施例2Ca/P比と、PGAによるカルシウム可溶化 Berrocalら(J.Dairy Researc
h,56:335(1989))は、Ca/P比が低い
場合、カルシウムを可溶化するのに必要なCPP−III
の量は多くなることを報告している。PGAについてこ
のような事実が存在するかどうかを検討するために、ま
ずPGA量とリン酸量を一定にして、種々のカルシウム
量でCa/P比を変えた場合を実施例2として、次にP
GA量とカルシウム量を一定にして種々のリン酸量でC
a/P比を変えた場合の可溶化を実施例3として検討し
た。Example 2 Ca / P Ratio and Calcium Solubilization by PGA Berrocal et al. (J. Dairy Research)
h, 56: 335 (1989)) is a CPP-III required to solubilize calcium when the Ca / P ratio is low.
Have been reported to increase. In order to examine whether such a fact exists for PGA, first, the case where the Ca / P ratio was changed with various amounts of calcium while keeping the amount of PGA and the amount of phosphoric acid constant, and then P
C with various amounts of phosphoric acid with constant amount of GA and calcium
Solubilization when the a / P ratio was changed was examined as Example 3.
【0010】カルシウム量でCa/P比を変えた場合 5〜80μモルのカルシウム溶液にPGA1.4mgを
加え、液量を3mlとし、リン酸溶液0.5ml(20
μモル)を加え、実施例1と同様上清カルシウム含量を
測定した。また同濃度のPGA−カルシウム混合液の液
量を2.5mlとり、リン酸溶液1.0ml(40μモ
ル)を加え同様に測定した。また、CPP−III 0.5
6mgを用いて同様に実験した。このPGA1.4m
g、CPP−III 0.56gは実施例1で16μモルの
カルシウムの80%(13μモル)を可溶化させた量で
ある。When the Ca / P ratio is changed by the amount of calcium, 1.4 mg of PGA is added to a calcium solution of 5 to 80 μmol to make the liquid volume 3 ml, and 0.5 ml of phosphoric acid solution (20
μmol) was added and the calcium content in the supernatant was measured as in Example 1. Further, 2.5 ml of the PGA-calcium mixed liquid having the same concentration was taken, and 1.0 ml (40 μmol) of phosphoric acid solution was added, and the same measurement was performed. Also, CPP-III 0.5
The same experiment was performed using 6 mg. This PGA 1.4m
g and CPP-III 0.56 g are the amounts obtained by solubilizing 80% (13 μmol) of 16 μmol of calcium in Example 1.
【0011】その結果をThe result
【図1】として示す。理論値は点線と実線で表され、測
定値は記号(○または●)で表されている。PGAの場
合(図1−a)、実測値は1.4mgのPGAが反応す
る13μモルの線より上部に分布していて、可溶化カル
シウム量は理論値より大きいことが示されている。一
方、CPP−III 0.56mgの場合(図1−b)、実
測値は13μモルの線より下部に分布していて可溶化カ
ルシウム量は理論値より少なくなる。このことはCaと
Pが当量という条件のときに決めたPGAとCPP−II
I のカルシウム80%可溶化能のおおよその基準(PG
A1.4mg=13μモルCa、CPP−III 0.56
mg=13μモルCa)と、カルシウムを少なくCa/
P比を低くした場合とで、かなりの誤差が生じてくるこ
とをしめしている。即ち、カルシウムやリン酸に対する
PGAとCPP−III の相互作用が同じではないことを
示している。FIG. 1 shows as. The theoretical value is represented by a dotted line and a solid line, and the measured value is represented by a symbol (○ or ●). In the case of PGA (Fig. 1-a), the measured values are distributed above the line of 13 µmol in which 1.4 mg of PGA reacts, indicating that the amount of solubilized calcium is larger than the theoretical value. On the other hand, in the case of 0.56 mg of CPP-III (FIG. 1-b), the measured values are distributed below the line of 13 μmol, and the amount of solubilized calcium is less than the theoretical value. This means that PGA and CPP-II decided when Ca and P were equivalent
Approximate standard of 80% calcium solubilization capacity of I (PG
A 1.4 mg = 13 μmol Ca, CPP-III 0.56
mg = 13 μmol Ca), which is low in calcium and Ca /
It is shown that a considerable error occurs when the P ratio is lowered. That is, it is shown that the interaction between PGA and CPP-III on calcium and phosphate is not the same.
【0012】実施例3リン酸量でCa/P比を変えた場合 16μモルのカルシウム溶液にPGA7.0、4.9、
2.0、0.56mgを加えそれぞれ3mlとし、リン
酸溶液0.5ml(8〜110μモル)を加え、実施例
1と同様に測定した。またCPP−III についても7.
0、2.0、0.56mgを加え、実施例1と同様に測
定した。Example 3 When the Ca / P ratio was changed depending on the amount of phosphoric acid , PGA 7.0, 4.9, and 16 μmol of calcium solution were added.
2.0 and 0.56 mg were added to make 3 ml each, and 0.5 ml (8 to 110 μmol) of phosphoric acid solution was added, and the same measurement as in Example 1 was carried out. Also for CPP-III 7.
0, 2.0, 0.56 mg was added, and the measurement was performed in the same manner as in Example 1.
【0013】その結果をThe result
【図2】として示す。理論線は実線で、実測値は記号
(○、●、△、□)で示した。PGAが7mg、4.9
mg(図2−aの(1),(2))、CPP−III が7
mg、2mg(図2−bの(1),(3))の場合、カ
ルシウムの可溶化はリン酸量に無関係に約16μモル
(約100%)である。PGAが2mgと0.56mg
(図2−aの(3)、(4))のとき、可溶化カルシウ
ム量は理論値に近く、リン酸48μモル(Ca/P=
0.33)まで可溶化カルシウム量は理論値に近く、リ
ン酸48μモル(Ca/P=0.33)まで可溶化カル
シウム量は理論値より多く、110μモルリン酸のとき
僅かに理論値を切る。FIG. 2 shows as. The theoretical line is a solid line, and the measured values are indicated by symbols (○, ●, Δ, □). 7 mg of PGA, 4.9
mg ((1) and (2) in FIG. 2-a), CPP-III is 7
In the case of mg and 2 mg ((1) and (3) in Fig. 2-b), the solubilization of calcium is about 16 µmol (about 100%) regardless of the amount of phosphoric acid. PGA is 2mg and 0.56mg
In the case of (3) and (4) in FIG. 2-a, the amount of solubilized calcium was close to the theoretical value, and 48 μmol of phosphoric acid (Ca / P =
The amount of solubilized calcium is close to the theoretical value up to 0.33), and the amount of solubilized calcium is larger than the theoretical value up to 48 μmol phosphoric acid (Ca / P = 0.33), and slightly less than the theoretical value when 110 μmol phosphoric acid. ..
【0014】[0014]
【発明の効果】γ−ポリグルタミン酸のカルシウム可溶
化能は、カゼインホスホペプチドと比較して1/2〜1
/7と評価できる。しかし、カゼインホスホペプチドの
作用がCa/P比に影響されるのに対して、γ−ポリグ
ルタミン酸はリン酸量の影響が少ないという特徴があ
る。The calcium-solubilizing ability of γ-polyglutamic acid is 1/2 to 1 as compared with casein phosphopeptide.
It can be evaluated as / 7. However, while the action of casein phosphopeptide is affected by the Ca / P ratio, γ-polyglutamic acid is characterized by being less affected by the amount of phosphate.
【0015】[0015]
【図1】:カルシウム量でCa/P比を変えた場合のP
GAとCPP−IIIのカルシウム可溶化量を示す。○は
20μモルリン酸の場合を示し、●は40μモルリン酸
の場合を示す。[Fig. 1]: P when the Ca / P ratio is changed by the amount of calcium
The amount of calcium solubilization of GA and CPP-III is shown. O indicates the case of 20 μmol phosphoric acid, and ● indicates the case of 40 μmol phosphoric acid.
【図2】:リン酸量でCa/P比を変えた場合のPGA
とCPP−III のカルシウム可溶化量を示す。FIG. 2: PGA when the Ca / P ratio is changed depending on the amount of phosphoric acid
And the amount of calcium solubilization of CPP-III are shown.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 魚谷 和道 神奈川県横浜市港北区師岡町760番地 明 治製菓株式会社薬品総合研究所内 (72)発明者 武部 英日 神奈川県横浜市港北区師岡町760番地 明 治製菓株式会社薬品総合研究所内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Kazumichi Uotani 760 Shimooka-cho, Kohoku-ku, Yokohama-shi, Kanagawa Meiji Confectionery Co., Ltd., Pharmaceutical Research Laboratory (72) Inventor Takebe Hideshi Shibuoka, Kita-ku, Yokohama-shi, Kanagawa Address 760 Meiji Seika Co., Ltd., Pharmaceutical Research Institute
Claims (1)
酸またはその塩を主成分とするカルシウム吸収促進効果
を有する健康飲食品1. A healthy food or drink containing calcium ions and γ-polyglutamic acid or a salt thereof as a main component and having a calcium absorption promoting effect.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP03260630A JP3112724B2 (en) | 1991-10-08 | 1991-10-08 | Healthy foods and drinks containing poly-gamma-glutamic acid as a main component |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP03260630A JP3112724B2 (en) | 1991-10-08 | 1991-10-08 | Healthy foods and drinks containing poly-gamma-glutamic acid as a main component |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0595767A true JPH0595767A (en) | 1993-04-20 |
JP3112724B2 JP3112724B2 (en) | 2000-11-27 |
Family
ID=17350593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP03260630A Expired - Fee Related JP3112724B2 (en) | 1991-10-08 | 1991-10-08 | Healthy foods and drinks containing poly-gamma-glutamic acid as a main component |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3112724B2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0605757A1 (en) * | 1992-11-25 | 1994-07-13 | Ajinomoto Co., Inc. | Compositions and goods containing minerals and poly-gamma-glutamic acid |
EP1723855A1 (en) * | 2005-05-16 | 2006-11-22 | Tung Hai Biotechnology Corporation | gamma-polyglutamic acid (gamma-PGA, H Form) and gamma-polyglutamates for use as nutrition supplements in dietary products |
JP2006316022A (en) * | 2005-05-16 | 2006-11-24 | Tung Hai Biotechnology Corp | gamma-POLYGLUTAMIC ACID (gamma-PGA, H FORM) AND gamma-POLYGLUTAMATE USED AS NUTRITION SUPPLEMENT IN DIETARY PRODUCT |
US20100136196A1 (en) * | 2007-05-31 | 2010-06-03 | Ajinomoto Co., Inc | Taste improver |
WO2011007864A1 (en) | 2009-07-16 | 2011-01-20 | 花王株式会社 | Inhibitor of blood gip level elevation |
WO2011007863A1 (en) | 2009-07-16 | 2011-01-20 | 花王株式会社 | Inhibitor of blood triglyceride level elevation |
JP2011046647A (en) * | 2009-08-27 | 2011-03-10 | Ajinomoto Co Inc | CHOLESTEROL INHIBITOR CONTAINING POLY-gamma-GLUTAMIC ACID |
WO2012096108A1 (en) | 2011-01-12 | 2012-07-19 | 花王株式会社 | Suppressor for increase in blood gip level, suppressor for increase in blood insulin level, postprandial blood triglyceride level reducing agent, and suppressor for increase in blood glucose level |
US8933025B2 (en) | 2009-07-16 | 2015-01-13 | Kao Corporation | Agent for suppressing postprandial elevation of blood insulin concentration |
US10494430B2 (en) | 2014-12-22 | 2019-12-03 | Kao Corporation | Anti-active GIP antibody |
-
1991
- 1991-10-08 JP JP03260630A patent/JP3112724B2/en not_active Expired - Fee Related
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0605757A1 (en) * | 1992-11-25 | 1994-07-13 | Ajinomoto Co., Inc. | Compositions and goods containing minerals and poly-gamma-glutamic acid |
EP1723855A1 (en) * | 2005-05-16 | 2006-11-22 | Tung Hai Biotechnology Corporation | gamma-polyglutamic acid (gamma-PGA, H Form) and gamma-polyglutamates for use as nutrition supplements in dietary products |
JP2006316022A (en) * | 2005-05-16 | 2006-11-24 | Tung Hai Biotechnology Corp | gamma-POLYGLUTAMIC ACID (gamma-PGA, H FORM) AND gamma-POLYGLUTAMATE USED AS NUTRITION SUPPLEMENT IN DIETARY PRODUCT |
US20100136196A1 (en) * | 2007-05-31 | 2010-06-03 | Ajinomoto Co., Inc | Taste improver |
US8853153B2 (en) | 2009-07-16 | 2014-10-07 | Kao Corporation | Agent for suppressing elevation of blood GIP concentration |
WO2011007863A1 (en) | 2009-07-16 | 2011-01-20 | 花王株式会社 | Inhibitor of blood triglyceride level elevation |
US8828935B2 (en) | 2009-07-16 | 2014-09-09 | Kao Corporation | Agent for suppressing elevation of blood triglyceride concentration |
WO2011007864A1 (en) | 2009-07-16 | 2011-01-20 | 花王株式会社 | Inhibitor of blood gip level elevation |
US8933025B2 (en) | 2009-07-16 | 2015-01-13 | Kao Corporation | Agent for suppressing postprandial elevation of blood insulin concentration |
JP2011046647A (en) * | 2009-08-27 | 2011-03-10 | Ajinomoto Co Inc | CHOLESTEROL INHIBITOR CONTAINING POLY-gamma-GLUTAMIC ACID |
WO2012096108A1 (en) | 2011-01-12 | 2012-07-19 | 花王株式会社 | Suppressor for increase in blood gip level, suppressor for increase in blood insulin level, postprandial blood triglyceride level reducing agent, and suppressor for increase in blood glucose level |
US9056066B2 (en) | 2011-01-12 | 2015-06-16 | Kao Corporation | Agent for suppressing elevation of blood GIP level, agent for suppressing elevation of blood insulin level, agent for lowering blood triglyceride level after meal ingestion, and agent for suppressing elevation of blood glucose level |
US10494430B2 (en) | 2014-12-22 | 2019-12-03 | Kao Corporation | Anti-active GIP antibody |
Also Published As
Publication number | Publication date |
---|---|
JP3112724B2 (en) | 2000-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kashket et al. | In-vitro inhibition of glucosyltransferase from the dental plaque bacterium Streptococcus mutans by common beverages and food extracts | |
US20070009638A1 (en) | Collagen-containing food and drink | |
EP2247200B1 (en) | The use of alternan as ingredient for certain foodstuffs | |
JPH11507842A (en) | Liquid oral composition comprising calcium compound and acidulant | |
US6500472B2 (en) | Folic acid and/or vitamin B12-lactoferrin complex | |
JPH0595767A (en) | Health food with gamma-polyglutamic acid as the chief ingredient | |
JP2006315985A (en) | Method for suppressing deterioration of vitamin | |
JP2007246413A (en) | Composition containing milk-originated basic protein | |
EP1219630B1 (en) | Immunopotentiating compositions | |
EP1430792B1 (en) | Food-additive slurry composition and powder composition, and food composition containing these | |
EP0097950B1 (en) | Stabilized aspartame composition, a process for its production and an aqueous food | |
US6251457B1 (en) | Stable preservation method of powdered soft drink preparation and powdered soft drink preparation | |
MXPA97001628A (en) | Use of eritritol in non-alcoholic beverages | |
WO2011125826A1 (en) | Ice cream or ice cream-like product and method for producing same | |
JPH11169145A (en) | Drink containing lactobacillus sporogenes | |
EP0007054A1 (en) | New whipping composition of modified whey protein and additives | |
JPH0499730A (en) | Browning-preventing agent | |
JP3698738B2 (en) | Iron absorption promoter containing guar gum enzyme degradation product as an active ingredient | |
JP2001089397A (en) | Physiologically active substance-containing tablet and method of preparing the same | |
JP2008125495A (en) | Calcium enriched liquid sugar | |
WO1996039048A1 (en) | Dry mix texture modified beverage using gellan gum | |
WO2019155956A1 (en) | Liquid composition for oral use containing collagen peptide, and method for alleviating the acidity of liquid composition for oral use | |
WO2004039178A1 (en) | Food additive composition and food composition containing the same | |
US9101148B2 (en) | Carbohydrate modifying agent and drinks containing the modifying agent | |
Juśkiewicz et al. | Effects of inulin supplemented to cellulose-free or cellulose-rich diets on caecal environment and biochemical blood parameters in rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070922 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080922 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090922 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100922 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110922 Year of fee payment: 11 |
|
LAPS | Cancellation because of no payment of annual fees |